We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioGenes Says Generic HCP Assays Provide Insufficient Sensitivity

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioGenes Says Generic HCP Assays Provide Insufficient Sensitivity"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
BioGenes GmbH has completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein (HCP) assay.

The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes. The continued use of generic HCP assays may lead to insufficient process documentation and finally to safety hazards for patients.

Generic HCP assays are commercially available and often used to minimize the costs of the sponsor in early phases of clinical development when the risk of drug failure is still high. They are used alongside the manufacturing process to monitor HCP-related impurities. As the development of highly sensitive process-specific HCP assays is associated with higher costs, such assays are usually not initiated until proof-of-concept.

"Our study results show that the generic HCP assay for CHO cells didn't perform as specified. Among five process-specific HCP assays that we have tested, one assay showed comparable and two showed even better performance than the generic assay, although the assays were developed for a specific process," said Dr. Alexander Knoll, Managing Director at BioGenes GmbH.

The higher sensitivity of some process-specific HCP assays was surprising as antibodies from process-specific assays are usually not as broadly reactive as those from generic assays.

"The generic assay's limitation also became obvious when we applied it to several HCP preparations. With one HCP standard only 20% of the proteins could be detected. With the other HCP standards 40% and 25% of the proteins were detected, respectively. For a generic assay intended to recognize a broad HCP population, we would have expected recovery rates above 70%," commented Dr. Alexander Knoll.

For biomanufacturers that use proprietary production cell lines for multiple products, so-called multiproduct HCP assays could provide a compromise between generic and process-specific assays. Multiproduct assays are generated against cell line specific HCP populations that are prepared from optimized cultivation and fermentation processes. Once developed, a multiproduct HCP assay can be applied like a generic assay except that it is far more sensitive and specific.

Multiproduct HCP assays ensure accurate HCP determination during process development, routine quality control, and final release testing. They can be optimized and validated to become process-specific, if necessary. Because these assays can be used for all products derived from a particular cell type or expression system, their development is a worthwhile investment.